Quick Facts

• Support for Cardiovascular Health: Used in patients to help manage the risk of certain vascular events.
• Post-Event Care: Indicated for individuals who have previously experienced a myocardial infarction or stroke.
• Management of Circulation Concerns: Appropriate for addressing concerns related to established peripheral arterial disease.
• Acute Coronary Syndrome: Utilized in the management of non-ST-elevation and ST-elevation acute coronary syndrome (ACS).

---

What Degregan Treats: Main Uses and Benefits

Degregan (clopidogrel) is a prescription medication utilized in appropriate patients to help reduce the occurrence of serious cardiovascular and cerebrovascular events. It is a recognized therapeutic option for individuals who have recently experienced a heart attack, also referred to as a myocardial infarction, or a stroke.

The medication is also indicated for the management of established peripheral arterial disease. Furthermore, Degregan is a component of a treatment strategy for patients presenting with certain forms of acute coronary syndrome (ACS), including non-ST-elevation myocardial infarction and unstable angina, as well as ST-elevation myocardial infarction.

Its therapeutic effect relates to assisting with blood flow in the vessels, which in turn helps manage the potential for the formation of certain blood clots that could lead to serious events in at-risk patients.

Degregan (clopidogrel) is generally indicated for use in adult patients but is subject to several strict exclusions and conditions defined by regulatory agencies.

Contraindications (Who Must Not Use Degregan)

Degregan is contraindicated in patients with:

• Active pathological bleeding, such as an intracranial hemorrhage or peptic ulcer [Source 1.2, 1.4].
• Known hypersensitivity to clopidogrel or any component of the product [Source 1.2].
• Severe hepatic impairment (severe liver disease) [Source 1.1].

Age and Condition-Based Restrictions

Population / Status	Official Eligibility Status
Pediatric Population	Use should not be made in children; safety and efficacy have not been established [Source 1.1, 3.1].
CYP2C19 Poor Metabolizers	Status is associated with diminished antiplatelet effect; use of an alternative P2Y12 inhibitor should be considered [Source 2.2, 3.1].
Renal/Moderate Hepatic Impairment	Therapeutic experience is limited; use with caution [Source 1.1].
Recent Ischemic Stroke	Cannot be recommended during the first 7 days after an acute event due to lack of data [Source 1.1].

For geriatric patients (ge75 years), no dose adjustment is required for the 75 mg regimen, but an official restriction applies to acute ST-elevation myocardial infarction, where the drug must be initiated without a loading dose [Source 3.2]. The use of Degregan during labor or delivery will increase the risk of maternal bleeding [Source 1.1].

Degregan (clopidogrel) has documented interactions with other medicines that are officially classified according to their effect on drug exposure or hemostasis.

Pharmacokinetic and Metabolic Interactions

The regulatory label highlights that certain substances reduce the concentration of clopidogrel's active metabolite in the bloodstream, diminishing its antiplatelet effect.

Category	Interacting Medicines	Regulatory Stance
CYP2C19 Inhibition	Omeprazole, Esomeprazole	AVOID CONCOMITANT USE
CYP2C19 Inhibitors	Ticlopidine, Fluoxetine, Fluconazole	Concomitant use should be discouraged

This interaction is due to inhibition of the CYP2C19 enzyme, and regulatory information notes that administering omeprazole or esomeprazole at a different time from Degregan does not prevent this effect. Conversely, a metabolite of clopidogrel is a strong inhibitor of CYP2C8, which can increase the systemic exposure of drugs like repaglinide.

Pharmacodynamic and Bleeding Risk Interactions

The official profile identifies numerous agents that may combine their antiplatelet or anticoagulant effects, resulting in an additive risk of bleeding.

• Oral Anticoagulants (e.g., Warfarin): Co-administration is not recommended due to increased bleeding intensity.
• NSAIDs and Other Antiplatelet Agents (e.g., Aspirin): Use requires caution due to an additive pharmacodynamic effect that increases the risk of hemorrhage.
• SSRIs and SNRIs are also documented as agents that may increase the risk of bleeding when taken with clopidogrel.

Population-Specific Notes

Official labeling notes that patients identified as CYP2C19 poor metabolizers due to genetic factors have reduced exposure to the active metabolite and, consequently, a diminished antiplatelet response.

Prodrug Bioactivation and Receptor Blockade

Clopidogrel is an inactive prodrug that requires an essential transformation step within the body. It must be metabolized, primarily by the CYP2C19 enzyme in the liver, to generate the pharmacologically active metabolite. This metabolic requirement dictates the onset characteristics of the effect and introduces variability in response among individuals. The active metabolite exerts its function by acting as an antagonist of the P2Y12 receptor on the surface of blood platelets. This interaction is characterized by irreversible, covalent binding to the receptor, permanently deactivating it for the lifespan of the platelet.

Anti-Aggregation Signaling Cascade

By permanently silencing the P2Y12 receptor, the drug prevents the platelet from responding to its key activation signal, ADP. The resulting blockade interrupts the inhibition of adenylyl cyclase, thereby maintaining high levels of intracellular cAMP. This preserved inhibitory signal suppresses the activation of the GPIIb/IIIa complex, the final molecular structure needed for platelets to link together. The outcome is a sustained functional paralysis of ADP-mediated aggregation, leading to a reduction in the blood's systemic aggregation capacity.

How to Use Degregan

Degregan (clopidogrel) is a film-coated tablet administered strictly via the oral route once daily. The use is governed by a precise dosing schedule detailing the initial amount and the frequency of administration.

Condition	Standard Dosing Regimen
Recent MI, Stroke, or PAD	75 mg once daily, without a loading dose.
Acute Coronary Syndrome (ACS)	Single 300 mg oral loading dose, followed by 75 mg once daily.

The 75 mg maintenance dose is taken once daily. For patients requiring a rapid antiplatelet effect, such as those with ACS, the initial 300 mg loading dose is required to accelerate therapeutic action. The drug may be taken with or without food.

Administration Rules

• Duration: Therapy is typically long-term for secondary prevention; however, for ACS, the duration may be specified, such as up to 12 months in combination with aspirin.
• Missed Dose: If a dose is missed by less than 12 hours from the usual time, it should be taken immediately. If more than 12 hours have passed, the missed dose must be skipped, and the patient should resume the regular schedule (do not double dose).
• Population Adjustments: In certain medically managed ST-Elevation MI patients over 75 years of age, the loading dose may be omitted. Patients identified as CYP2C19 poor metabolizers are advised to discuss alternative P2Y12 inhibitors.

Research evidence / Overview of studies for Degregan

---

## Evidence for Reducing Vascular Events After Stroke or Heart Attack

Degregan was evaluated in research exploring long-term outcomes for adults who have already experienced a serious vascular event, such as a heart attack (MI) or an ischemic stroke. Research also explored outcomes in individuals with established Peripheral Arterial Disease (PAD). The primary research involved large-scale, international randomized controlled trials (RCTs) that measured the recurrence of non-fatal stroke, non-fatal MI, or death related to vascular causes. Findings describe patterns observed across the study periods. Research notes that individual response may vary due to certain genetic differences, and the results apply only to the populations studied.

## Evidence for Acute Coronary Syndrome (ACS) Management

Research explored the use of Degregan as part of a combination therapy, typically with aspirin, for patients experiencing an Acute Coronary Syndrome (ACS). These short-term RCTs measured the occurrence of acute changes, such as cardiovascular death, recurrent MI, or stroke, during the initial period of care. Studies report how symptoms evolved in the observed populations. Research is ongoing to determine the most appropriate duration for this combination therapy, and long-term effects are not fully established in this context.

## Evidence for Long-Term Use and Subgroup Evaluation

Research explored whether Degregan, as a single antiplatelet therapy, was associated with certain long-term outcomes for patients who have previously undergone coronary stenting (PCI). These trials measured vascular events over extended periods. Separately, research has explored outcomes in several specific patient subgroups, including older adults and those with concerns related to kidney function. Data for certain groups remain insufficient compared to the main study populations, and in some cases, certain findings were mixed.

## Research Gaps and Areas of Uncertainty

While a substantial research base was developed for Degregan's primary uses, several areas remain uncertain. The comparative evidence is lacking between Degregan and certain newer agents, and subgroup findings for patients with multiple concurrent health issues are uncertain. This body of research highlights what is known — and what is still uncertain — and research provides context but not individual predictions.

Key Studies & References

1. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial (COMMIT/CCS-2)
2. FDA Drug Label Plavix (clopidogrel) and CYP2C19 Genotype-Specific Dosing
3. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Common questions about Degregan (FAQ)

---

Q: If I'm a CYP2C19 poor metabolizer, what does that mean for my treatment with Degregan?

According to official product information, CYP2C19 poor metabolizers are individuals whose bodies are less able to convert clopidogrel (Degregan) into its active form. This reduced conversion may result in a lower level of antiplatelet protection, which could affect the drug's efficacy in preventing events like heart attack or stroke. Regulatory documents advise healthcare providers to consider alternative treatments for patients identified as poor metabolizers.

---

Q: How should I dispose of Degregan if I have unused tablets?

If a medicine take-back program is available in your area, this is the recommended way to dispose of unused or expired tablets. When a take-back program is unavailable, official guidelines describe a process where the tablets may be mixed with an unappealing substance (such as dirt or used coffee grounds), placed in a sealed plastic bag, and discarded in the household trash. To maintain water quality, official instructions state that the medicine should not be flushed down the toilet.

---

Q: What happens if Degregan is taken with blood thinners like Warfarin?

Official labeling and studies indicate that taking Degregan with oral anticoagulants, such as warfarin, is generally not recommended. This combination may cause an additive effect on blood thinning, which increases the overall risk of bleeding. For this reason, co-administration is not advised without medical oversight.

---

Q: What should I do if I get a cut or bleed while taking this drug?

Since Degregan works by making it harder for blood to clot, cuts or injuries may take longer than usual to stop bleeding. Patients are generally advised to apply pressure to a cut. Medical attention should be sought if any bleeding is unanticipated, prolonged, or excessive, including signs of internal bleeding like blood in the stool or urine.

---

Q: Is there a generic version of Degregan available?

Yes, regulatory records confirm that the active ingredient in Degregan, clopidogrel bisulfate, is available in multiple FDA-approved generic tablet versions. These generic options contain the same active ingredient and meet the necessary standards for approval.

---

Q: Does Degregan interact with alcohol?

The official safety profile for Degregan highlights that excessive alcohol consumption may increase the risk of stomach bleeding. Because this medication is an antiplatelet agent that also increases bleeding risk, consuming alcohol may further raise that risk. Patients concerned about alcohol use should consult their healthcare provider.

---

Q: What is the maximum dose of Degregan that I can take in a day?

The daily dose is determined by the healthcare provider and the condition being treated. Regulatory information includes a 75 mg maintenance dose and a 300 mg loading dose for certain acute conditions. Taking more than the prescribed amount is generally not advised, as it may increase the potential for serious adverse effects.

Official Storage and Handling Requirements

Degregan tablets must be stored at Controlled Room Temperature, which is defined in regulatory documents as 20 C to 25 C (68 F to 77 F). The product can tolerate brief temperature excursions between 15 C and 30 C (59 F and 86 F). The official label mandates that the tablets be protected from moisture and light.

To ensure product stability, the medication must be kept in its original container and the container must be tightly closed. Storage in high-humidity areas, such as a bathroom, is prohibited. Furthermore, Degregan must be stored out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Unused or expired Degregan should be discarded through an authorized drug take-back program. If this option is unavailable, regulatory guidance permits disposal in household trash by following a specific preparation procedure: mixing the tablets (do not crush) with an unappealing substance like dirt or used coffee grounds, placing the mixture in a sealed plastic bag, and then throwing it away. Disposal of the medicine into wastewater is prohibited.